US doctors likely to keep denosumab as second- or third-line therapy for PMO
This article was originally published in Scrip
Executive Summary
The majority of US clinicians surveyed by Decision Resources would use Amgen's investigational monoclonal antibody Prolia (denosumab), which is given by subcutaneous injection twice yearly, as either a second- or third-line therapy for osteoporosis if the product receives regulatory approval for the indication.